Protara Therapeutics (TARA) Cash & Equivalents (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Cash & Equivalents data on file, last reported at $14.7 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 83.89% year-over-year to $14.7 million in Q1 2026; TTM through Mar 2026 was $14.7 million, a 83.89% decrease from a year earlier, with the FY2025 full-year figure at $49.7 million, down 69.5% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $14.7 million, down from $49.7 million in the prior quarter.
• Over the last five years, Cash & Equivalents for TARA reached as high as $162.8 million in Q4 2024 and fell as low as $12.6 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $52.1 million across 5 years, with a median of $39.6 million in 2023.
• Across the five-year window, Cash & Equivalents jumped 311.25% in 2024 and plunged 83.89% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $94.7 million in 2022, then plunged by 58.19% to $39.6 million in 2023, then soared by 311.25% to $162.8 million in 2024, then plunged by 69.5% to $49.7 million in 2025, then sank by 70.32% to $14.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $14.7 million in Q1 2026, $49.7 million in Q4 2025, and $12.6 million in Q3 2025.